Matinas BioPharma (MTNB) Tops Q2 EPS by 1c

Matinas BioPharma (NYSE: MTNB) reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03).

For earnings history and earnings-related data on Matinas BioPharma (MTNB) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• Lumexa Imaging Holdings, Inc. (LMRI) Reports In-Line Q2 EPS; Offers Guidance
• Acrivon Therapeutics, Inc. (ACRV) Tops Q2 EPS by 21c